Lomustine
As palliative or supplementary treatment,usually in combination with radiotherapy and/or surgery as part of multiple drug regimens in:
Brain tumours (primary or metastatic)
Lung tumours (especially oat-cell carcinoma)
Hodgkin's disease (resistant to conventional combination chemotherapy)
Malignant melanoma (metastatic)
Lomustine "medac" may also be of value as second-line treatment in Non-Hodgkin's lymphoma, myelomatosis, gastrointestinal tumours, carcinoma of the kidney, the testis, the ovary, the cervix uteri and the breast.
